NATCO Pharma Limited (BOM:524816)

NATCO Pharma Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Revenue	34,846	40,783	44,295	39,988	27,071	19,448
Other Revenue	-	-	24	32	14	14
Revenue	34,846	40,783	44,319	40,020	27,085	19,462
Revenue Growth	-20.73%	-7.98%	10.74%	47.76%	39.17%	-5.34%
Cost of Revenue	6,050	6,905	7,274	7,487	6,544	5,845
Gross Profit	28,796	33,878	37,045	32,533	20,541	13,617
Selling, General & Admin	6,975	6,872	5,991	5,309	4,625	4,806
Other Operating Expenses	11,301	12,641	9,029	9,599	6,072	5,952
Operating Expenses	20,237	21,579	17,383	16,827	12,443	12,383
Operating Income	8,559	12,299	19,662	15,706	8,098	1,234
Interest Expense	-465	-367	-170	-120	-148	-132
Interest & Investment Income	-	-	1,905	1,013	513	392
Earnings From Equity Investments	1,309	466	-	-	-	-
Currency Exchange Gain (Loss)	-	-	198	103	214	103
Other Non Operating Income (Expenses)	2,951	2,976	271	14	130	-3
EBT Excluding Unusual Items	12,354	15,374	21,866	16,716	8,807	1,594
Merger & Restructuring Charges	-	-	-	-	-291	-11
Gain (Loss) on Sale of Investments	-	-	14	-7	-52	12
Gain (Loss) on Sale of Assets	-	-	901	-17	178	427
Asset Writedown	-	-	-30	-	-23	-
Pretax Income	12,354	15,374	22,914	16,735	8,619	2,022
Income Tax Expense	907	1,189	4,080	2,852	1,466	322
Earnings From Continuing Operations	11,447	14,185	18,834	13,883	7,153	1,700
Net Income to Company	11,447	14,185	18,834	13,883	7,153	1,700
Minority Interest in Earnings	-4	-	20	-	-	-
Net Income	11,443	14,185	18,854	13,883	7,153	1,700
Net Income to Common	11,443	14,185	18,854	13,883	7,153	1,700
Net Income Growth	-32.59%	-24.76%	35.81%	94.09%	320.76%	-61.44%
Shares Outstanding (Basic)	179	179	179	179	183	182
Shares Outstanding (Diluted)	179	179	179	179	183	182
Shares Change	-0.00%	-0.00%	-0.21%	-1.67%	0.08%	-0.04%
EPS (Basic)	63.89	79.20	105.26	77.34	39.18	9.32
EPS (Diluted)	63.89	79.20	105.26	77.34	39.18	9.32
EPS Growth	-32.59%	-24.76%	36.10%	97.40%	320.39%	-61.42%

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	-	13,800	12,957	8,722	7,028	-1,863
Free Cash Flow Per Share	-	77.05	72.34	48.59	38.50	-10.21
Dividend Per Share	4.500	5.000	6.000	9.500	5.500	4.500
Dividend Growth	-10.00%	-16.67%	-36.84%	72.73%	22.22%	-14.29%
Gross Margin	82.64%	83.07%	83.59%	81.29%	75.84%	69.97%
Operating Margin	24.56%	30.16%	44.37%	39.25%	29.90%	6.34%
Profit Margin	32.84%	34.78%	42.54%	34.69%	26.41%	8.73%
Free Cash Flow Margin	-	33.84%	29.24%	21.79%	25.95%	-9.57%
EBITDA	10,697	14,365	21,442	17,506	9,669	2,600
EBITDA Margin	30.70%	35.22%	48.38%	43.74%	35.70%	13.36%
D&A For EBITDA	2,138	2,066	1,780	1,800	1,571	1,366
EBIT	8,559	12,299	19,662	15,706	8,098	1,234
EBIT Margin	24.56%	30.16%	44.37%	39.25%	29.90%	6.34%
Effective Tax Rate	7.34%	7.73%	17.81%	17.04%	17.01%	15.93%
Revenue as Reported	37,797	43,759	47,840	41,269	28,117	20,438
Advertising Expenses	-	-	-	-	-	326

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 20, 2026

Data Sources Report a data error